{"entity":{"id":"nct07590531","kind":"trial","name":"AMT-116 in Combination With AK112 in Patients With Lung Cancer","aka":[],"tldr":"A phase 1/2 trial of Ivonescimab in non-small-cell lung cancer and small-cell lung cancer, run by Multitude Therapeutics Inc., now recruiting.","summary":"AMT-116 in Combination With AK112 in Patients With Lung Cancer is a phase 1/2 interventional study registered as NCT07590531 by Multitude Therapeutics Inc., with 118 participants planned, started 2026-06-29 and due to reach its primary completion in 2027-05-30. Interventions recorded: AMT-116, AK112. Conditions listed: Advanced Non-small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07590531","url":"https://clinicaltrials.gov/study/NCT07590531"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["ivonescimab"],"companies":["multitude-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07590531","phase":"1/2","setting":"An Open-label, Multicenter Phase Ib/II Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMT116 in Combination With Ivonescimab (AK112) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)","sponsor":"Multitude Therapeutics Inc.","enrolled":118,"outcomes":[]},"route":"/trials/nct07590531/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"amt-116","kind":"drug","name":"AMT-116","route":"/drugs/amt-116/"},{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/"}],"company":[{"id":"multitude-therapeutics","kind":"company","name":"Multitude Therapeutics","route":"/companies/multitude-therapeutics/"}]}}